In hepatocytes from NAFLD patients, cyanidin-3-O-glucoside significantly decreases triglyceride, NLRP3, Caspase-1, IL-1β, IL-18 and ROS levels, and increases the expressions of PINK1, Parkin and TOM20 proteins. The gene discussed is PRKN; the disease is metabolic dysfunction-associated steatotic liver disease.